ArticleDiscover oncology2025
IGF1/IGF1R signaling promotes the expansion of liver CSCs and serves as a potential therapeutic target in HCC.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Insulin-like growth factor receptor signaling in physiology and disease.Signal transduction and targeted therapy · 2026Review
- Context-dependent duality of senescent cells in liver fibrosis.Liver research (Beijing, China) · 2026Review
- Translational insights and clinical challenges of targeting cancer stem cells.Signal transduction and targeted therapy · 2026Review
- Review
- Loss of protein phosphatase 1 regulator TIMAP protein triggers EMT in A549 cells.Cell communication and signaling : CCS · 2026Article
- Review
- The endocrine role of hepatokines: implications for human health and disease.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The presence of cancer stem cells (CSCs) play important roles in hepatocellular carcinoma (HCC) relapse, metastasis, drug resistance. The IGF1/IGF-1R signaling pathway has been implicated in the development and progression of various cancers, and plays an important role in maintaining the stemness of various types of CSCs, but its role in liver CSCs remains unclear. Here, we report that IGF1R is highly expressed in HCC tumors and positively correlated with stemness markers. To further verify the role of IGF1R in liver CSCs, the positive correlation of IGF1R expression with liver CSCs was also validated in mRNA level using the TCGA database. After pretreatment with IGF1 or overexpression of IGF1R, we observed a expansion of CD133 + and CD90 + populations and concomitantly a increased expression of CSC-associated genes, and increased sphere formation. Furthermore, IGF1R inhibition by inhibitor effectively eliminated liver CSCs and inhibited the growth of tumors and metastasis in vivo. These findings uncover the important role of IGF1/IGF1R signaling in liver CSCs, and also provide a promising diagnostic marker as well as therapeutic intervention for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.